Plenary Speakers |
|
Dr. Nektarios Tavernarakis | Chairman of the Board of Directors, Foundation for Research and Technology-Hellas (FORTH)
Research Director, Institute of Molecular Biology and Biotechnology (IMBB) Professor of Molecular Systems Biology, Medical School of the University of Crete, in Heraklion, Greece |
Dr. Nektarios Tavernarakis is the Chairman of the Board of Directors at the Foundation for Research and Technology-Hellas (FORTH), Research Director at the Institute of Molecular Biology and Biotechnology (IMBB), and Professor of Molecular Systems Biology at the Medical School of the University of Crete, in Heraklion, Greece. He is the Founder and first Director of the Graduate Program on BioInformatics at the Medical School of the University of Crete, and is also heading the Neurogenetics and Ageing laboratory of IMBB. He is an elected corresponding member of the Academy of Athens, an elected member and Vice President of the Scientific Council of the European Research Council (ERC), and an elected Chairman of the European Institute of Innovation and Technology (EIT) Governing Board and Executive Committee, the American Association for the Advancement of Science (AAAS), the European Molecular Biology Organization (EMBO), the German National Academy of Sciences (Leopoldina), the European Academy of Sciences and Arts, and Academia Europaea. He has also served as the Director of the Institute of Molecular Biology and Biotechnology. |
|
Dr. Colin Brenan |
CEO, Kibur Medical Inc. |
Dr. Colin Brenan is a serial life sciences entrepreneur who is presently the CEO of Kibur Medical Inc., an early-stage company commercializing a novel approach to precision cancer therapies and diagnostics from simultaneous and in situ molecular profiling of tumor response to up to 20 drugs or drug combinations with an implantable microdevice. Previously he was Founder/CEO and Director of the single cell instrumentation company 1CellBio Inc. (www.1cell-bio.com); formerly Founder/Chief Commercial Officer and Director of antibody drug developer HiFiBiO Ltd (www.hifibio.com); and, Managing Director of the Monsanto-Atlas Seed Fund Alliance at Atlas Venture (Cambridge, USA) where he identified and invested in seed and early-stage life science companies.
|
|
Dr. Tanya Kanigan | Chief Analytics Officer
Genomic Expression Inc. |
Dr. Tanya Kanigan is a scientist, inventor, and entrepreneur with 25 years of experience developing and commercializing tools for medical research. In her current position as Chief Analytics Officer at Genomic Expression Inc. (Beverly, MA) she develops bio- and clinical informatics pipelines for precision oncology. Formerly, as COO and Principal Scientist of Biocogniv Inc (Burlington, VT) she developed diagnostic tests for COVID-19 and pulmonary embolism based on machine learning analysis of routine lab results. Earlier in her career she co-founded an MIT spin-out called BioTrove that developed the OpenArrayTM nanofluidic array technology, now owned by Thermo Fisher Scientific and widely used in pharmacogenetics testing, miRNA analysis and infectious disease research. As an independent consultant, Dr. Kanigan also advises early-stage life science companies on technology commercialization strategy and serves as a reviewer for the NIH SBIR program. |
|
Dr. Kristy K. Brock |
Professor, The University of Texas MD Anderson Cancer Center |
Dr. Kristy K. Brock received her PhD in Nuclear Engineering and Radiological Sciences from the University of Michigan. After receiving her PhD, she joined the faculty at the University of Toronto (Radiation Medicine Program, Princess Margaret Hospital) and subsequently the faculty at the University of Michigan (Department of Radiation Oncology). She is currently a Professor with tenure in the Department of Imaging Physics at the University of Texas MD Anderson Cancer Center, where she is the Director for the Image-Guided Cancer Therapy Research Program. Her research has focused on image guided cancer therapy, where she has developed a biomechanical model-based deformable image registration algorithm to integrate imaging into treatment planning, delivery, and response assessment as well as to understand and validate imaging signals through correlative pathology. Her algorithm was licensed and incorporated into a commercial treatment planning system.
|
|
Dr. Aldo Faisal | Professor
Imperial College London |
Dr. Aldo Faisal (@FaisalLab) is Professor of Artificial Intelligence & Neuroscience at the Dept. of Bioengineering and the Dept. of Computing at Imperial College London, where he leads the Brain & Behaviour Lab [www.faisallab.org] and is the holder of a UKRI Turing AI Fellowship. He is the Director of the £20Mio UKRI Centre for Doctoral Training in AI for Healthcare since 2019 and the Behaviour Analytics Lab at the Data Science Institute (London) since 2017. Aldo works at the interface of Machine Learning, Neuroscience and translational Biomedical engineering to help people in diseases and health. Core to his research discovery and technology innovation work is the idea that both artificial and human intelligence have common roots in the understanding, learning and generation of behaviour. He currently is one of the few engineers world-wide that lead their own clinical trials to validate their technology, His work received a number of prizes and awards, including the $50,000 Research Discovery Prize by the Toyota Foundation. |
|
Prof. Dimitrios Fotiadis | Professor, Biomedical Engineering
Department of Materials Science and Engineering University of Ioannina |
Prof. Dimitrios Fotiadis received the Diploma degree in chemical engineering from the National Technical University of Athens, Athens, Greece, in 1985, and the Ph.D. degree in chemical engineering and materials science from the University of Minnesota, Minneapolis, in 1990. He is currently a Professor of Biomedical Engineering in the Department of Materials Science and Engineering, University of Ioannina, Ioannina, Greece, where he is also the Director of the Unit of Medical Technology and Intelligent Information Systems, and is also an Affiliated Member of Foundation for Research and Technology Hellas, Institute of Molecular Biology and Biotechnology, Dept. of Biomedical Research. He was a Visiting Researcher at the RWTH, Aachen, Germany, and the Massachusetts Institute of Technology, Boston. He has coordinated and participated in more than 200 R&D funded projects. He is the author or coauthor of more than 220 papers in scientific journals, 400 papers in peer-reviewed conference proceedings, and more than 45 chapters in books. He is also the editor or coeditor of 25 books. His work has received more than 8500 citations (h-index = 46). He is a senior member of IEEE, member of IEEE Technical Committee of information Technology in Healthcare and the Editor in Chief of IEEE Journal of Biomedical and Health Informatics and Associate Editor for Computers in Biology and Medicine. His research interests include multiscale modeling of human tissues and organs, intelligent wearable/implantable devices for automated diagnosis, processing of big medical data, sensor informatics, image informatics, and bioinformatics. |
|
Dr. David Clifton | Professor
Clinical Machine Learning, University of Oxford |
Dr. David Clifton is Professor of Clinical Machine Learning in the Department of Engineering Science of the University of Oxford, and Official Fellow in AI & Machine Learning at Reuben College, Oxford. He is a Research Fellow of the Royal Academy of Engineering, and a Fellow of Fudan University, China.
|
|
Dr. May D. Wang | Professor
Georgia Institute of Technology and Emory University |
Dr. May D. Wang is a full professor, GCC distinguished cancer scholar and Director of Biocomputing and Bioinformatics Core in Emory-Georgia Tech Cancer Nanotechnology Center at the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. Dr. Wang's primary research interest is biomedical and health informatics in systems medicine and healthcare, with the goal to speed up the discovery, development, and translation in modern biology, medicine, and health. She has played an active role in several working groups within National Cancer Institute (NCI/NIH) cancer Biomedical Informatics Grid (caBIG), and FDA-led Microarray Quality Control Consortium (MAQC) on biomarker and nanomedicine for personalized medicine. As the corresponding or co-corresponding author, Dr. Wang has published in journals such as Annals of Biomedical Eng, BMC Bioinformatics, Trends in Biotechnology, Nature Protocols, Proceedings of National Academy of Sciences, Annual Review of Medicine, and the Pharmacogenomics Journal. |
|
|